Carisma Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Carisma Therapeutics (NASDAQ:CARM) Third Quarter 2024 Results

Key Financial Results

• Revenue: US$3.39m (down 12% from 3Q 2023).
• Net loss: US$12.7m (loss narrowed by 41% from 3Q 2023).
• US$0.30 loss per share (improved from US$0.53 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Carisma Therapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 14%.

Looking ahead, revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 21%.

Performance of the American Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 6 warning signs for Carisma Therapeutics (3 are potentially serious!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.